---
slug: ara-290-glp1-agonists
title: "ARA-290 × GLP-1 agonists (class)"
kind: standard
status: published
hash: 8a0f97942653ef9a6816f6e3c1db07d0331b2a5d0e685d69c1b6bf24b67eadad
created: 2026-08-08T04:23:00.685Z
updated: 2026-10-08T11:31:10.973Z
summary: "glp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits. Studied for nerve repair and small-fiber"
tags: ["peptide"]
above: []
below: []
adjacent: []
nested: []
---
# ARA-290 × GLP-1 agonists (class)

*glp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits. Studied for nerve repair and small-fiber*

## Regeneration vs degeneration — where this fits

glp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits.

## What is known

Studied for nerve repair and small-fiber regeneration in neuropathy models.

Target condition: glp1 agonists.
Body system: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss..

## Logic chain

1. ara-290 studied for nerve repair and small-fiber regeneration in neuropathy models..
2. glp1 agonists involves metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. dysfunction.
3. If ara-290 reaches the affected tissue, it may shift the repair/breakdown balance.
4. This chain is tested in animal or lab models only.

## Parent peptide claims relevant here

- ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).
- In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients.
- ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions.
- In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner.
- Commercial vendors and clinics market this compound (17 commercial/clinic sources catalogued) — marketing material, not evidence.

## Evidence tier

Preclinical — animal and in vitro studies only. No published human trials for this specific combination.

## What we do not know

- Whether ara-290 reaches glp1 agonists tissue at functional concentrations
- Optimal dosing, route, and duration for this target
- Interaction with standard-of-care treatments for glp1 agonists
- Long-term safety profile in this population

## Safety note

All peptide use for glp1 agonists is research-context only. Not medical advice. Consult a physician before any experimental compound.

## Facts

```json
{
  "converted_from": "markdown",
  "original_updated": "2026-07-17T02:38:12.395Z",
  "register": "standard",
  "category": null
}
```